GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 164   

Articles published

GSK 40.24 +0.08 (0.21%)
price chart
Momentum Biotech Stock's Update: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) closed at $40.16 with trading volume of 2.78 million shares down its average volume of 3.52 million.
Here's how GlaxoSmithKline plc (ADR) Hopes To Trump Gilead Sciences In HIV Market
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been facing a very troubled pharmaceutical business over the last few years.
GlaxoSmithKline plc (ADR) To Lead Asthma Market
GlaxoSmithKline Plc ADR (NYSE:GSK) can expect to secure approval from European regulators as early as this week for Nucala, its new biotech drug to treat severe asthma.
GlaxoSmithKline plc (ADR) (GSK) Stock Update - Takeover Rumors Drive Recent Gain
GlaxoSmithKline plc. (ADR) (NYSE:GSK) stock has gone up 7.48% since the release of its higher-than-expected second quarter fiscal '15 (2QFY15) earnings on July 29.
GlaxoSmithKline plc (ADR) (NYSE:GSK) Cautious After Legionnaire Bug Found in ...  Wall Street Observer
GlaxoSmithKline plc (ADR) Stock Update: Drug-Maker In Hot Water Again
British pharmaceutical giant GlaxoSmithKline Plc (ADR) (NYSE:GSK) has seen a gloomy stock performance so far this year, with only a few steep increases barely able to offset the many declines.
British Stocks Trading on U.S. Exchanges: GlaxoSmithKline plc (ADR) (NYSE ...  Wall Street Point
3 Best European Stocks: Unilever plc (UL), GlaxoSmithKline plc (GSK ...  News Oracle
Should Gilead Sciences, Inc. Fear GlaxoSmithKline plc (ADR)?
Gilead Sciences, Inc. (NASDAQ:GILD) and GlaxoSmithKline plc (ADR) (NYSE:GSK) seem to be battling for a larger share of the HIV market.
GlaxoSmithKline plc (ADR), AbbVie Inc: Attractive High-Yield Dividend Pharma ...
yield Bob Ciura: The stock market sell-off is painful for investors who own stocks, but the good news is that declining stock prices present new buying opportunities.
GlaxoSmithKline plc (ADR) Presents Improved Valuation And Dividend Yield ...
In a research report dated September 7, Bank of America Merrill Lynch upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) to Neutral from Underperform, while reiterating its price target of 1,450p on the stock.
GlaxoSmithKline plc (ADR) (GSK) Stock Update: Mixed Signals For Investors
GlaxoSmithKline Plc (ADR) (NYSE:GSK) stock has performed moderately well so far this year, marked with some steep increases and declines as well.
GlaxoSmithKline plc (ADR) Mega-Merger Talk: Johnson & Johnson, Roche Holding ...
New takeover rumors for GlaxoSmithKline Plc. (ADR) (NYSE:GSK) emerged Monday. Daily Mail UK reported that UK dealers were speculating Roche Holding Ltd.